Skip to main content
Home
Latest news
Browse topics
Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH

Cardiovascular disease and diabetes medication

Highlights

07-14-2018 | Metformin | Review | Article

Should metformin remain first-line medical therapy for patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease? An alternative approach

Harrington JL et al. Curr Diab Rep 2018; 18: 64. doi: 10.1007/s11892-018-1035-z

06-22-2018 | Hypertension | Review | Article

The optimal blood pressure target in diabetes mellitus: A quest coming to an end?

Papadopoulou E et al. J Hum Hypertens 2018. doi: 10.1038/s41371-018-0079-5

06-21-2018 | Sleep disorders | Article

Relationship between sleep disturbance and self-care in adults with type 2 diabetes

Zhu B et al. Acta Diabetol 2018. doi: 10.1007/s00592-018-1181-4

06-08-2018 | Insulin resistance | Review | Article

Chronic kidney disease-induced insulin resistance: Current state of the field

Dave N, Wu J, Thomas S. Curr Diab Rep 2018; 18: 44. doi: 10.1007/s11892-018-1010-8

05-28-2018 | Lifestyle interventions | Case report | Article

Successful management of poorly controlled type 2 diabetes with multidisciplinary neurobehavioral rehabilitation: A case report and review

Deng Z et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0448-7

05-24-2018 | Diet | Article

Intake of cocoa products and risk of type-2 diabetes: The multiethnic cohort

Maskarinec G et al. Eur J Clin Nutr 2018. doi: 10.1038/s41430-018-0188-9

05-15-2018 | Diet | Article

Glycemic impact of non-nutritive sweeteners: A systematic review and meta-analysis of randomized controlled trials

Nichol AD, Holle MJ, An R. Eur J Clin Nutr 2018. doi: 10.1038/s41430-018-0170-6

05-15-2018 | Type 2 diabetes | Article

Prevalence and incidence of complications at diagnosis of T2DM and during follow-up by BMI and ethnicity: A matched case–control analysis

Owusu Adjah ES et al. Cardiovasc Diabetol 2018; 17: 70. doi: 10.1186/s12933-018-0712-1

04-24-2018 | Cardiovascular disorders | Highlight | News

Patients with type 2 diabetes and CVD may receive suboptimal treatment

Specialist physicians and antidiabetic medications reported to confer cardiovascular benefit are being underutilized by patients with type 2 diabetes and cardiovascular disease, US study data show.

04-03-2018 | Alogliptin | Highlight | News

Support for alogliptin as add-on therapy for type 2 diabetes

Adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin and sulfonylurea treatment may improve glycemic control in patients with type 2 diabetes and high cardiovascular risk, a post-hoc analysis of the EXAMINE trial suggests.

03-12-2018 | Canagliflozin | Highlight | News

CANVAS analysis supports SGLT2 inhibitor benefits for HF

The latest analysis of the CANVAS trial indicates that the cardiovascular benefits of canagliflozin in patients with type 2 diabetes may be greatest in those with concomitant heart failure.

02-13-2018 | Older adults | Editorial | Article

Does setting treatment targets risk the overtreatment of type 2 diabetes in older patients?

The drive to achieve lower HbA1c targets in older patients is not without concern or risk. Our UK Board address concerns highlighted by recent trials and discuss whether current guidelines do enough to mitigate the risks of overtreatment.

Editorial Board member Jay Shubrook follows up with treatment individualization specialist David Strain on the treatment challenges presented by older adults, and the implications for tailoring hypertension therapy in this diverse population (11:08).



Learning points include:

  • The rationale for emphasizing quality over quantity of life in certain subsets of the elderly patient population.
  • The importance of incorporating understanding of key comorbidities into treatment planning, including:
    • Left ventricular and/or diastolic dysfunction
    • Chronic kidney disease 
    • Benign prostatic hyperplasia
    • Heart failure
  • Single/multi-agent therapies capable of targeting hypertension and its comorbidities.
  • The importance of early renal function testing in older adults initiated on treatments for hypertension and its comorbidities.
  • Understanding renal impairment risks in vulnerable adults treated with angiotensin-converting-enzyme (ACE) inhibitors in patients.
  • Understanding the relative risk of hyponatremia with generally well-tolerated treatments like as thiazide diuretics.
  • Best practice for avoiding adverse drug events in the acute setting.
  • The challenges associated with treating concomitant heart failure in older adults.

« Video 4: Individualization of diabetes treatment: Considerations for frail, elderly patients with heart failure

Editorial Board member Jay Shubrook and Advisory Board member Robert Chilton get together once more to discuss best practice tips for identifying and treating hypertension in patients with pre-existing diabetes (12:17).



Learning points include:

  • Strategies to avoid common pitfalls when performing blood pressure measurements.
  • The importance of the blood pressure measurements in determining the risk of cardiovascular events.
  • The benefits of dual-action and preload-targeted therapies in hypertensive patients.
  • Why potassium levels are an important factor to consider before initiating treatment.

« Video 2: Why aren't we reaching blood pressure goals, despite the raised target?



Video 4: Individualization of diabetes treatment: Considerations for frail, elderly patients with heart failure »

In the wake of the revised blood pressure targets, recommended by the American Diabetes Association's 2017 Position Statement and 2018 Standards of Care, Editorial Board member Jay Shubrook and Advisory Board member Robert Chilton discuss clinical approaches to get hypertensive diabetes patients to target more consistently (12:29).


Learning points include:

  • The atherogenic risk posed by diabetes and why blood pressure measurements from the arm-alone may not be sufficient to evaluate the threat in all patients.
  • The benefits and drawbacks of the medication classes indicated for hypertension treatment, such as:
    • Diuretics
    • β-blockers
    • Calcium channel blockers
  • The impact and rationale for targeting blood pressures lower than those indicated in the ADA position statement. 

« Video 2: What are the current recommendations for managing high blood pressure in diabetes patients?



Video 3: When to intervene in patients with diabetes and high blood pressure? »

11-22-2017 | Cardiovascular disorders | Editorial | Article

Diabetes in special situations: Sodium-glucose co-transporter-2 inhibitors in acute coronary syndrome

Editorial Board member Sanjay Kalra presents a pragmatic approach to the use of sodium-glucose co-transporter-2 inhibitors in patients affected by acute coronary syndromes.

10-23-2017 | Cardiovascular disorders | Editorial | Article

Diabetes in special situations: Glucagon-like peptide-1 receptor agonist use in acute myocardial infarction

Editorial Board member Sanjay Kalra presents a pragmatic approach to the use of glucagon-like peptide-1 receptor agonists in patients affected by acute myocardial infarction.

07-18-2017 | SGLT2 inhibitors | Review | Article

Practical approach to initiating SGLT2 inhibitors in type 2 diabetes

The authors review potential adverse events related to initiating SGLT2 inhibitors and propose a treatment algorithm for the adjustment of concomitant therapies after initiating therapy.

01-13-2017 | Cardiovascular outcomes | Editorial | Article

Clinical implications of cardiovascular outcomes trials in type 2 diabetes

What do the results of CVOTs mean for practicing clinicians? Medicine Matters contributor, Carol Wysham reviews the latest evidence and guidelines for reducing CV risk in patients with type 2 diabetes.

Previous
Image Credits